Prof. Dr. Jürgen Krauss

Dr. Jürgen Krauss

Dear client,
For better user experience, you need modern browsers that are up-to-date. The version of your browser you are using is out of date; this poses a security risk. Please use another browser.
Thank you for your understanding.

Prof. Dr. Jürgen Krauss, MD


Jürgen Krauss is co-founder and Medical Expert of Heidelberg ImmunoTherapeutics. In this role he is member of the leadership team and brings in intense clinical and medical expertise. He is an accomplished researcher and experienced clinician in the field of innovative cancer therapeutics development. Since 2016, Jürgen Krauss is heading the Section for Clinical Immunotherapy at the National Center for Tumor Diseases Heidelberg (NCT). In this function he has established an infrastructure for conducting early clinical immunotherapy trials following his main interest to efficiently translate academic research into successful clinical applications. He also directs the ‘Antibody-based Immunotherapeutics Development Group’ at the NCT. The group has generated several antibody-based immunotherapeutics until the late preclinical development stage including its lead product HDIT101 being clinically developed by Heidelberg ImmunoTherapeutics. Before assuming his current position, Jürgen Krauss served as clinical oncologist and research group leader at Essen University Hospital from 2004 to 2008. Prior to that he held a research position at the National Cancer Institute (NCI) of the National Institute of Health (NIH) in the United States where he conducted cancer research and was responsible for the preclinical drug development of antibody targeted ribonucleases as novel anti-cancer drugs. He studied medicine at the Universities of Mainz and Berlin and received his doctorate from the Charité in Berlin.